Innovative Science in Virology, Oncology, and Neurology
Allogeneic CD8+ T cell therapies from a single donor to treat thousands for the first time
CD8+ Cytotoxic T-Lymphocytes
CD8+ T-Lymphocytes, also known as Cytotoxic or Killer T Cells, represent one of nature’s most powerful weapons against disease. To date, these cells have not been harnessed to their full potential for clinical application. Currently available approaches include both genetically unmodified T cells applied to the treatment of viruses early after transplant and genetically modified CAR-T cells used to treat a selected subset of malignancies.
Tevogen’s proprietary approach allows genetically unmodified T cell products to be generated with a much higher CD8+ content and better-defined target specificity. The ability to fully harness this powerful tool is not too far away.
CD8+ Cytotoxic T lymphocytes identify and kill by recognizing antigenic peptides on the surface of the infected or malignant cells.
Highly Efficient Ratio of Doses per Cell Donor
Tevogen’s commercial scale ready first generation manufacturing process already yields a highly efficient ratio of doses per cell donor. The second generation, Tevogen’s proprietary TCR-T process, is expected to dramatically increase the number of doses.
Highly Purified, Target-Specific Cytotoxic CD8+ T Lymphocyte (CTL)
Our patented approach, using pre-defined T cell targets, allows virus infected cells, viral induced cancer cells, and several non-virally induced cancers to be directly targeted by Tevogen’s T cell products. Nature uses this approach to rid us of virus infections. Many cancer cells can be targeted and killed in the same way.
Technology to Bring Targets for Tevogen’s Allogeneic CD8+ Cytotoxic T Lymphocytes to Cancer Cells Being Marked for Elimination
In some cases, cancer cells may not express an ideal T cell target on their own. It is possible to bring a well-recognized target to the cancer cells using monoclonal antibodies or liposomes. This allows the Tevogen’s target specific cytotoxic T cells to then attack the cancer cells.
Unlike CAR-T or BITE antibody approaches which recruit a very heterogeneous group of T cells to the tumor, Tevogen’s approach instead focuses a highly purified population of killer T cells on the tumor, with far more potential to accomplish the task of eradicating the cancer.
“At the end of the day, it’s not about analysis of expenses and profits, it’s about the wife that will lose her husband, it’s about the granddaughter that will lose her grandfather. It’s about you and me. It’s about stopping this carnage.”
– Ryan Saadi
New Jersey, USA
© 2023 Tevogen Bio. All Rights Reserved.